Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1158/1541-7786.MCR-20-0814 http://scihub22266oqcxt.onion/10.1158/1541-7786.MCR-20-0814 33328281!ä!33328281 Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33328281&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Mol+Cancer+Res 2021 ; 19 (4): 549-554 Nephropedia Template TP {{tp|p=33328281|t=2021. Relevance of the Bruton Tyrosine Kinase as a Target for COVID-19 Therapy |pdf=|usr=}}{{33328281}} gab.com Text Relevance of the Bruton Tyrosine Kinase as a Target for COVID-19 Therapy JO: Mol Cancer Res http://www.kidney.de/pget.php?&tw=1&pmid=33328281 #FOAvip The outbreak of the novel coronavirus disease 2019 (COVID-19) has emerged as one of the biggest global health threats worldwide. As of October 2020, more than 44 million confirmed cases and more than 1,160,000 deaths have been reported globally, and the toll is likely to be much higher before the pandemic is over. There are currently little therapeutic options available and new potential targets are intensively investigated. Recently, Bruton tyrosine kinase (BTK) has emerged as an interesting candidate. Elevated levels of BTK activity have been reported in blood monocytes from patients with severe COVID-19, compared with those from healthy volunteers. Importantly, various studies confirmed empirically that administration of BTK inhibitors (acalabrutinib and ibrutinib) decreased the duration of mechanical ventilation and mortality rate for hospitalized patients with severe COVID-19. Herein, we review the current information regarding the role of BTK in severe acute respiratory syndrome coronavirus 2 infections and the suitability of its inhibitors as drugs to treat COVID-19. The use of BTK inhibitors in the management of COVID-19 shows promise in reducing the severity of the immune response to the infection and thus mortality. However, BTK inhibition may be contributing in other ways to inhibit the effects of the virus and this will need to be carefully studied. Twit Text FOAVip Relevance of the Bruton Tyrosine Kinase as a Target for COVID-19 Therapy ????Mol Cancer Res http://www.kidney.de/pget.php?&tw=1&pmid=33328281 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33328281 #FOAvip English Wikipedia <ref>{{Cite pmid|33328281}}</ref> Relevance of the Bruton Tyrosine Kinase as a Target for COVID-19 Therapy #MMPMID33328281 Rada M; Qusairy Z; Massip-Salcedo M; Macip S Mol Cancer Res 2021[Apr]; 19 (4): 549-554 PMID33328281show ga The outbreak of the novel coronavirus disease 2019 (COVID-19) has emerged as one of the biggest global health threats worldwide. As of October 2020, more than 44 million confirmed cases and more than 1,160,000 deaths have been reported globally, and the toll is likely to be much higher before the pandemic is over. There are currently little therapeutic options available and new potential targets are intensively investigated. Recently, Bruton tyrosine kinase (BTK) has emerged as an interesting candidate. Elevated levels of BTK activity have been reported in blood monocytes from patients with severe COVID-19, compared with those from healthy volunteers. Importantly, various studies confirmed empirically that administration of BTK inhibitors (acalabrutinib and ibrutinib) decreased the duration of mechanical ventilation and mortality rate for hospitalized patients with severe COVID-19. Herein, we review the current information regarding the role of BTK in severe acute respiratory syndrome coronavirus 2 infections and the suitability of its inhibitors as drugs to treat COVID-19. The use of BTK inhibitors in the management of COVID-19 shows promise in reducing the severity of the immune response to the infection and thus mortality. However, BTK inhibition may be contributing in other ways to inhibit the effects of the virus and this will need to be carefully studied. |*COVID-19 Drug Treatment[MESH] |Adenine/analogs & derivatives/pharmacology[MESH] |Agammaglobulinaemia Tyrosine Kinase/*antagonists & inhibitors/metabolism[MESH] |Antiviral Agents/adverse effects/*pharmacology[MESH] |Benzamides/pharmacology[MESH] |COVID-19/complications/enzymology[MESH] |Humans[MESH] |Lung/drug effects/virology[MESH] |Molecular Targeted Therapy[MESH] |Neoplasms/drug therapy/virology[MESH] |Piperidines/pharmacology[MESH] |Protein Kinase Inhibitors/adverse effects/pharmacology[MESH] |Pyrazines/pharmacology[MESH]Relevance of the Bruton Tyrosine Kinase as a Target for COVID-19 Thera(epmc).pdf DeepDyve Pubget Overpricing